摘要
重组单克隆抗体对特定抗原具有专一性和有效性。人们针对不同的适应证,已开发出许多特异性的治疗性抗体药物。目前已发现,在抗体药物开发中IgG框架类型不仅可影响治疗性抗体的理化性质,还可影响治疗性抗体的活性及治疗效果。因此,在抗体药物开发策略中应将IgG亚型的选择列入考虑范围。由于IgG4亚型独特的生物学特点,使得它已用于一些不需要效应功能的治疗性抗体的开发。本文主要对治疗性抗体药物开发中IgG4亚型抗体的研究及应用现状进行综述,以期为抗体药物的开发提供新的思路。
Many specific therapeutic antibody drugs have been developed for different indications. In drug development, it has been found that the antibody isotype framework can not only affect the physical and chemical properties of therapeutic antibodies, but also influence the activity and therapeutic effect. As a result, IgG isotype selection should be considered carefully in antibody drug development strategies. Because of the unique biological characteristics, IgG4 isotype has been used in some therapeutic antibodies for which effector functions are not desired. In order to provide new ideas for the development of antibody drugs, the research and application progress of IgG4 isotype in therapeutic antibody drug development has been reviewed.
出处
《药学学报》
CAS
CSCD
北大核心
2015年第7期802-807,共6页
Acta Pharmaceutica Sinica
基金
"重大新药创制"国家科技重大专项创新型人源单抗药物研制平台及重大品种开发资助项目(2014ZX09201041)
